Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)

被引：254

作者：

Jin, Jing ^{[1
,2
,3
,4
]}

Tang, Yuan ^{[1
,2
]}

Hu, Chen ^{[5
]}

Jiang, Li-Ming ^{[1
,6
]}

Jiang, Jun ^{[1
,6
]}

Li, Ning ^{[1
,2
]}

Liu, Wen-Yang ^{[1
,2
]}

Chen, Si-Lin ^{[1
,2
]}

Li, Shuai ^{[7
]}

Lu, Ning-Ning ^{[1
,2
]}

Cai, Yong ^{[7
]}

Li, Yong-Heng ^{[7
]}

Zhu, Yuan ^{[8
]}

Cheng, Guang-Hui ^{[9
]}

Zhang, Hong-Yan ^{[10
]}

Wang, Xin ^{[11
]}

Zhu, Su-Yu ^{[12
,13
]}

Wang, Jun ^{[14
]}

Li, Gao-Feng ^{[15
]}

Yang, Jia-Lin ^{[16
]}

Zhang, Kuan ^{[17
]}

Chi, Yihebali ^{[1
,18
]}

Yang, Lin ^{[1
,18
]}

Zhou, Hai-Tao ^{[1
,19
]}

Zhou, Ai-Ping ^{[1
,18
]}

Zou, Shuang-Mei ^{[1
,20
]}

Fang, Hui ^{[1
,2
]}

Wang, Shu-Lian ^{[1
,2
]}

Zhang, Hai-Zeng ^{[1
,19
]}

Wang, Xi-Shan ^{[1
,19
]}

Wei, Li-Chun ^{[21
]}

Wang, Wen-Ling ^{[22
]}

Liu, Shi-Xin ^{[23
]}

Gao, Yuan-Hong ^{[24
]}

Li, Ye-Xiong ^{[1
,2
]}

机构：

[1] State Key Lab Mol Oncol, Beijing 100021, Peoples R China

[2] Canc Hosp, Dept Radiat Oncol, Chinese Acad Med Sci CAMS & Peking Union Med Coll, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China

[3] Canc Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr, Shenzhen, Guangdong, Peoples R China

[4] Shenzhen Hosp, CAMS & PUMC, Shenzhen, Peoples R China

[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Biostat & Bioinformat, Sch Med, Baltimore, MD USA

[6] Canc Hosp, Dept Radiol, CAMS & PUMC, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China

[7] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[8] Zhejiang Canc Hosp, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Dept Radiat Oncol,Canc Hosp,Chinese Acad Sci, Hangzhou, Peoples R China

[9] Jilin Univ, China Japan Union Hosp, Dept Radiat Oncol, Changchun, Peoples R China

[10] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Radiat Oncol, Div Life Sci & Med, Hefei, Anhui, Peoples R China

[11] Sichuan Univ, West China Hosp, Dept Radiat Oncol, Chengdu, Peoples R China

[12] Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Peoples R China

[13] Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China

[14] Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[15] Beijing Hosp, Natl Ctr Gerontol, Inst Geriatr Med, Dept Radiat Oncol,CAMS, Beijing, Peoples R China

[16] Sichuan Prov Canc Hosp, Dept Radiat Oncol, Chengdu, Peoples R China

[17] Qinghai Red Cross Hosp, Dept Radiat Oncol, Xining, Qinghai, Peoples R China

[18] Canc Hosp, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,CAMS & PUMC, Beijing, Peoples R China

[19] Canc Hosp, Dept Colorectal Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,CAMS & PUMC, Beijing, Peoples R China

[20] Canc Hosp, Dept Pathol, Natl Canc Ctr, Natl Clin Res Ctr Canc,CAMS & PUMC, Beijing, Peoples R China

[21] Air Force Med Univ, Xijing Hosp, Dept Radiat Oncol, Xian, Peoples R China

[22] Guizhou Med Univ, Dept Oncol, Affiliated Hosp, Guiyang, Peoples R China

[23] Jilin Prov Canc Hosp, Dept Radiat Oncol, Changchun, Jilin, Peoples R China

[24] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 15期

基金：

中国国家自然科学基金;

关键词：

TOTAL MESORECTAL EXCISION; PREOPERATIVE CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; OPEN-LABEL; CHEMORADIATION; OXALIPLATIN; CAPECITABINE; FLUOROURACIL; OUTCOMES;

D O I：

10.1200/JCO.21.01667

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE To ascertain if preoperative short-term radiotherapy followed by chemotherapy is not inferior to a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer. MATERIALS AND METHODS Patients with distal or middle-third, clinical primary tumor stage 3-4 and/or regional lymph node-positive rectal cancer were randomly assigned (1:1) to short-term radiotherapy (25 Gy in five fractions over 1 week) followed by four cycles of chemotherapy (total neoadjuvant therapy [TNT]) or chemoradiotherapy (50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine [chemoradiotherapy; CRT]). Totalmesorectal excision was undertaken 6-8 weeks after preoperative treatment, with two additional cycles of CAPOX (intravenous oxaliplatin [130 mg/m(2), once a day] on day 1 and capecitabine [1,000 mg/m(2), twice a day] from days 1 to 14) in the TNT group and six cycles of CAPOX in the CRT group. The primary end point was 3-year disease-free survival (DFS). RESULTS Between August 2015 and August 2018, a total of 599 patients were randomly assigned to receive TNT (n = 302) or CRT (n = 297). At a median follow-up of 35.0 months, 3-year DFS was 64.5% and 62.3% in TNT and CRT groups, respectively (hazard ratio, 0.883; one-sided 95% CI, not applicable to 1.11; P < .001 for noninferiority). There was no significant difference in metastasis-free survival or locoregional recurrence, but the TNT group had better 3-year overall survival than the CRT group (86.5% v 75.1%; P = .033). Treatment effects on DFS and overall survival were similar regardless of prognostic factors. The prevalence of acute grade III-V toxicities during preoperative treatment was 26.5% in the TNT group versus 12.6% in the CRT group (P < .001). CONCLUSION Short-term radiotherapy with preoperative chemotherapy followed by surgery was efficacious with acceptable toxicity and could be used as an alternative to CRT for locally advanced rectal cancer. (C) 2022 by American Society of Clinical Oncology

引用

页码：1681 / +

页数：15

共 34 条

[1] Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal - A randomized controlled trial
Ajani, Jaffer A.
Winter, Kathryn A.
Gunderson, Leonard L.
Pedersen, John
Benson, Al B., III
Thomas, Charles R., Jr.
Mayer, Robert J.
Haddock, Michael G.
Rich, Tyvin A.
Willett, Christopher
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (16): : 1914 - 1921
[2] [Anonymous], Clinical Practice Guidelines in Oncology (NCCN Guidelines)
[3] [Anonymous], 2003, COMMON TERMINOLOGY C
[4] Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Bahadoer, Renu R.
Dijkstra, Esmee A.
van Etten, Boudewijn
Marijnen, Corrie A. M.
Putter, Hein
Kranenbarg, Elma Meershoek-Klein
Roodvoets, Annet G. H.
Nagtegaal, Iris D.
Beets-Tan, Regina G. H.
Blomqvist, Lennart K.
Fokstuen, Tone
ten Tije, Albert J.
Capdevila, Jaume
Hendriks, Mathijs P.
Edhemovic, Ibrahim
Cervantes, Andres
Nilsson, Per J.
Glimelius, Bengt
van de Velde, Cornelis J. H.
Hospers, Geke A. P.
[J]. LANCET ONCOLOGY, 2021, 22 (01) : 29 - 42
[5] Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
Braendengen, Morten
Tveit, Kjell M.
Berglund, Ake
Birkemeyer, Elke
Frykholm, Gunilla
Pahlman, Lars
Wiig, Johan N.
Bystrom, Per
Bujko, Krzysztof
Glimelius, Bengt
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3687 - 3694
[6] Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial
Breugom, A. J.
van Gijn, W.
Muller, E. W.
Berglund, A.
van den Broek, C. B. M.
Fokstuen, T.
Gelderblom, H.
Kapiteijn, E.
Leer, J. W. H.
Marijnen, C. A. M.
Martijn, H.
Kranenbarg, E. Meershoek-Klein
Nagtegaal, I. D.
Pahlman, L.
Punt, C. J. A.
Putter, H.
Roodvoets, A. G. H.
Rutten, H. J. T.
Steup, W. H.
Glimelius, B.
van de Velde, C. J. H.
[J]. ANNALS OF ONCOLOGY, 2015, 26 (04) : 696 - 701
[7] Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study
Bujko, K.
Wyrwicz, L.
Rutkowski, A.
Malinowska, M.
Pietrzak, L.
Krynski, J.
Michalski, W.
Oledzki, J.
Kusnierz, J.
Zajac, L.
Bednarczyk, M.
Szczepkowski, M.
Tarnowski, W.
Kosakowska, E.
Zwolinski, J.
Winiarek, M.
Wisniowska, K.
Partycki, M.
Beczkowska, K.
Polkowski, W.
Stylinski, R.
Wierzbicki, R.
Bury, P.
Jankiewicz, M.
Paprota, K.
Lewicka, M.
Cisel, B.
Skorzewska, M.
Mielko, J.
Bebenek, M.
Maciejczyk, A.
Kapturkiewicz, B.
Dybko, A.
Hajac, L.
Wojnar, A.
Lesniak, T.
Zygulska, J.
Jantner, D.
Chudyba, E.
Zegarski, W.
Las-Jankowska, M.
Jankowski, M.
Kolodziejski, L.
Radkowski, A.
Zelazowska-Omiotek, U.
Czeremszynska, B.
Kepka, L.
Kolb-Sielecki, J.
Toczko, Z.
Fedorowicz, Z.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (05) : 834 - 842
[8] Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy
Bujko, K
Nowacki, MP
Nasierowska-Guttmejer, A
Michalski, W
Bebenek, AB
Pudelko, M
Kryj, A
Oledzki, J
Szmeja, J
Sluszniak, J
Serkies, K
Kladny, J
Pamucka, A
Kukolowicz, P
[J]. RADIOTHERAPY AND ONCOLOGY, 2004, 72 (01) : 15 - 24
[9] Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial
Bujko, Krzysztof
Michalski, Wojciech
Kepka, Lucyna
Nowacki, Marek P.
Nasierowska-Guttmejer, Anna
Tokar, Piotr
Dymecki, Dariusz
Pawlak, Mariusz
Lesniak, Tadeusz
Richter, Piotr
Wojnar, Andrzej
Chmielik, Ewa
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (02): : 369 - 377
[10] Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
Cisel, B.
Pietrzak, L.
Michalski, W.
Wyrwicz, L.
Rutkowski, A.
Kosakowska, E.
Cencelewicz, A.
Spalek, M.
Polkowski, W.
Jankiewicz, M.
Stylinski, R.
Bebenek, M.
Kapturkiewicz, B.
Maciejczyk, A.
Sadowski, J.
Zygulska, J.
Zegarski, W.
Jankowski, M.
Las-Jankowska, M.
Toczko, Z.
Zelazowska-Omiotek, U.
Kepka, L.
Socha, J.
Wasilewska-Tesluk, E.
Markiewicz, W.
Kladny, J.
Majewski, A.
Kapuscinski, W.
Suwinski, R.
Bujko, K.
[J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1298 - 1303

← 1 2 3 4 →